Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.39 |
| ▸ | WEE1 | P30291 | 3/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | CCND2 | P30279 | 1/20 | 0.34 |
| ▸ | CCND3 | P30281 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041546 | 0.91 | WEE1 (0.41) | CDK4CDK6WEE1PTK2TNK2 | |
| SCHEMBL15036198 | 0.91 | CDK4 (0.39) | CDK4CDK6WEE1CCND1EGFR | |
| SCHEMBL15041548 | 0.85 | PTK2 (0.51) | PTK2JAK3 | |
| SCHEMBL15041541 | 0.83 | PTK2 (0.53) | CDK4WEE1PTK2TNK2CCND1 | |
| SCHEMBL15036199 | 0.83 | CDK4 (0.42) | CDK4CDK6WEE1CCND1EGFR | |
| SCHEMBL15041892 | 0.83 | WEE1 (0.50) | CDK4CDK6WEE1PTK2TNK2 | |
| SCHEMBL15259472 | 0.82 | PAK3 (0.52) | CDK4CDK6WEE1TNK2CCND1 | |
| SCHEMBL15041540 | 0.82 | PTK2 (0.49) | PTK2 | |
| SCHEMBL15036493 | 0.80 | CDK4 (0.39) | CDK4CDK6CCND1CCND2CCND3 | |
| SCHEMBL15034962 | 0.77 | CDK4 (0.36) | CDK4CDK6WEE1CCND1CCND2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680099-B2 | 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20130245012-A1 | 6-(ETHYNYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245012-A1 | 6-(ETHYNYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK3 | CDK4 397/4885CDK6 163/4885WEE1 763/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CDK4 404/4885CDK6 435/4885WEE1 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.